According to Zacks, “Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company’s lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts. “
A number of other research analysts have also recently commented on the company. JPMorgan Chase & Co. began coverage on Aprea Therapeutics in a research report on Monday, October 28th. They set a neutral rating and a $23.00 price target on the stock. ValuEngine cut Aprea Therapeutics from a buy rating to a hold rating in a research report on Thursday, November 14th. Royal Bank of Canada began coverage on Aprea Therapeutics in a research report on Monday, October 28th. They set an outperform rating and a $33.00 price target on the stock. Finally, Morgan Stanley began coverage on Aprea Therapeutics in a research report on Monday, October 28th. They set an equal weight rating and a $23.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $26.33.
APRE stock opened at $40.30 on Monday. Aprea Therapeutics has a 1-year low of $15.10 and a 1-year high of $53.11. The stock has a fifty day simple moving average of $36.40.
Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 14th. The company reported ($5.29) EPS for the quarter, beating analysts’ consensus estimates of ($5.88) by $0.59. As a group, equities analysts expect that Aprea Therapeutics will post -2.93 EPS for the current year.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.
Featured Article: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.